Clinical Trial Update: A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease. [Phase 3]

View source ↗

Summary

A Phase 3 study of subcutaneous Mircera for anemia in pre-dialysis chronic kidney disease participants was terminated, and results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 3 | Status: TERMINATED | Results posted: 2016-04-01